Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder or Post-Traumatic Stress Disorder, amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been issued Israeli patent number 241757...

Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Israel

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the sale of a $12.0 million senior secured...

Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible Note

NEW YORK, Nov. 9, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 3rd International...

Seelos Therapeutics to Participate in the 3rd International Conference on Sanfilippo Syndrome and Related Diseases

NEW YORK, Sept. 9, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Closing of $7.0 Million Registered Direct Offering

NEW YORK, Sept. 4, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Pricing of $7.0 Million Registered Direct Offering

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc.

Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis

NEW YORK, July 16, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that on July 15, 2020, the compensation committee of.

Seelos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aeglea BioTherapeutics

Dynavax Technologies

Liquidia Technologies Inc

PhaseBio Pharmaceuticals Inc

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several Top Shorts today.

Top Stocks To Short As Markets Rebound Ignores Disappointing Monday

SLS-002 Was Safe and Well Tolerated Across All Doses with Resolution of Expected Group Mean Dissociative Side-Effects That Occurred in the Higher Dose Groups Within One Hour   Food and Drug Administration Feedback from Type C Meeting Supported the Design of a 16 Day Study for Acute Suicidal Ideation and Behavior (ASIB) in Patients with Major Depressive Disorder (MDD); Study to Begin in Fall 2020   Seelos to Host Key Opinion Leader Call Today at 1 p.m. Eastern Time

Seelos Therapeutics Announces Final Data from Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002) and Clinical Development Plans

NEW YORK, June  15, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to provide updates regarding data from the Phase I study of SLS-002 on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. Seelos will also provide an overview of the design for Seelos’ next study of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD) during the call.

Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002

Seelos Therapeutics (NASDAQ: SEEL) shares are trading higher on Thursday after the company announced the initiation of a preclinical study of SLS-004 In Parkinson's Disease.

Why Seelos Therapeutics Is Trading Higher Today

Gene Therapy Program to Target the Regulation of the SNCA Gene of Alpha-Synuclein Gene Therapy Program to Target the Regulation of the SNCA Gene of Alpha-Synuclein

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease

NEW YORK, May  15, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Judith Dunn, Ph.D. to its Board of Directors.

Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors

NEW YORK, May  15, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has been granted Rare Pediatric Disease Designation (RPDD) for SLS-005 in Sanfilippo syndrome from the U.S. Food and Drug Administration (FDA).

Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

NEW YORK, May  04, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos' U.S. patent number 10,437,637 (application number 16/263,707) titled “COMPOSITIONS AND METHODS FOR TREATING AN AGGREGATION DISEASE OR DISORDER” for trehalose (SLS-005).

Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)

NEW YORK, April  30, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has been granted Orphan Drug Designation (ODD) for SLS-005 in Sanfilippo syndrome from U.S. Food and Drug Administration (FDA).

Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome

NEW YORK, April  08, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provides its first quarter business update and pipeline developments.

Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments

Seelos Completed Type C Meeting with FDA to Discuss Trial Design for Study of SLS-002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder Seelos Completed Type C Meeting with FDA to Discuss Trial Design for Study of SLS-002 for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)

NEW YORK, March  16, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. The net proceeds to Seelos from this offering are expected to be approximately $3.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Seelos. Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates.

Seelos Therapeutics Announces Closing of Public Offering of Common Stock

NEW YORK, March  11, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 1,125,000 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.

Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock

NEW YORK, March  11, 2020  (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has received a written response from the European Medicines Agency (EMA), in lieu of a face to face meeting, offering guidance for Seelos’ planned European study of SLS-005 (IV trehalose) in patients with mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome.

Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome

Seelos Producing Viral Vectors and Preparing for In-Vivo Study in Parkinson's Disease Seelos Producing Viral Vectors and Preparing for In-Vivo Study in Parkinson's Disease

Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007

Jazz Pharmaceuticals

Supernus Pharmaceuticals

Jazz Pharma's Mixed Earnings, And Other News: The Good, Bad And Ugly Of Biopharma

News for Seelos Therapeutics Stock (SEEL)